Results 101 to 110 of about 529 (145)

Phase 1/2 study of IMC-C103C, a T cell receptor bispecific (MAGE-A4×CD3) ImmTAC targeting MAGE-A4-expressing malignancies. [PDF]

J Immunother Cancer
Sweis RF, Melero I, Davar D, Garralda E, Hamid O, Chen HA, Evans TRJ, Moore KN, Sacco JJ, Thistlethwaite F, Williams A, Blumenschein GR, Callahan MK, Johnson ML, Schenk EL, Wustner J, Stanhope S, Tao K, Marshall S, Lopez J.   +19 more
europepmc   +1 more source

Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial. [PDF]

Nat Med
Kendra KL, Bellasea SL, Eroglu Z, Hu-Lieskovan S, Campbell KM, Carson WE, Wada DA, Plaza JA, Sosman JA, In GK, Ikeguchi A, Hyngstrom J, Brohl AS, Khushalani NI, Markowitz J, Negrea G, Kasbari S, Doolittle GC, Swami U, Roberts T, Mathew BN, Medina E, Baselga-Carretero I, Gonzalez CR, Garcilazo IP, Vega-Crespo A, Chen JM, Naser Al-Deen N, Patel SP, Sharon E, Moon J, Wu MC, Ribas A.   +32 more
europepmc   +1 more source

Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial. [PDF]

Nat Med
Yap TA, Sweis RF, Vaishampayan U, Kilari D, Gainor JF, McKean M, Barve M, Tarhini AA, Bockorny B, Sonpavde G, Park D, Babu S, Ju Y, Liu L, Henry S, Tirucherai GS, DeWall S, Qatanani M, Marantz JL, Gan L.   +19 more
europepmc   +1 more source

Alkali-Activated Slag as Sustainable Binder for Pervious Concrete and Structural Plaster: A Feasibility Study. [PDF]

Materials (Basel)
Coffetti D, Rapelli S, Coppola L.
europepmc   +1 more source

Prednisolone modulates CD8⁺ and regulatory T-cell activity to dampen response to immune checkpoint inhibitor therapy in melanoma. [PDF]

Oncoimmunology
Brown JR, Pedersen B, Long GV, Maher NG, Lim SY, Rizos H, Shklovskaya E.   +6 more
europepmc   +1 more source

First-in-human phase I open-label study of the anti-TIM-3 monoclonal antibody INCAGN02390 in patients with select advanced or metastatic solid tumors. [PDF]

Oncologist
Gutierrez ME, Tang SC, Powderly JD, Balmanoukian AS, Hoyle PE, Dong Z, Cheng L, Gong X, Janik JE, Bourayou N, Hamid O.   +10 more
europepmc   +1 more source

Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From <i>EGFR</i>-Mutant NSCLC Informs Potential Therapeutic Targets. [PDF]

JTO Clin Res Rep
Zhang B, Lewis W, Stewart CA, Morris BB, Solis LM, Serrano A, Xi Y, Wang Q, Lopez ER, Concannon K, Heeke S, Tang X, Raso G, Cardnell RJ, Vokes N, Blumenschein G, Elamin Y, Fosella F, Tsao A, Skoulidis F, Hume CB, Sasak K, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Tran H, Zhang J, Gibbons D, Vaporciyan A, Wang J, Park K, Heymach JV, Byers LA, Gay CM, Le X.   +35 more
europepmc   +1 more source

Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies. [PDF]

J Hematol Oncol
Ouyang Q, Rodon J, Liang Y, Wu X, Li Q, Song L, Yan M, Tong Z, Liu Y, Wainberg ZA, Wang Y, Geng C, Ulahannan SV, Yu G, Sharma MR, Wang X, Wang JS, Spira A, Zhao W, Sanborn RE, Cheng Y, Wang X, Liu G, Li Y, Ge J, Chartash E, Akala OO, Yin Y.   +27 more
europepmc   +1 more source

Longitudinal Tracking of <i>ALK</i>-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNA. [PDF]

JTO Clin Res Rep
Heeke S, Gandhi S, Tran HT, Lam VK, Byers LA, Gibbons DL, Gay CM, Altan M, Antonoff MB, Le X, Tu J, Saad MB, Pek M, Poh J, Ngeow KC, Tsao A, Cascone T, Negrao MV, Wu J, Blumenschein GR, Heymach JV, Elamin YY.   +21 more
europepmc   +1 more source

A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve <i>EGFR</i>-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial). [PDF]

J Clin Oncol
Le X, Patel JD, Shum E, Baik C, Sanborn RE, Shu CA, Kim C, Fidler MJ, Hall R, Elamin YY, Tu J, Blumenschein G, Zhang J, Gibbons D, Gay C, Mohindra NA, Chae Y, Boumber Y, Sabari J, Santana-Davila R, Rogosin S, Herzberg B, Creelan B, Pellini B, Tanvetyanon T, Heeke S, Hernandez M, Gray JE, Saltos A, Heymach JV.   +29 more
europepmc   +1 more source